Integrative pharmacogenomic analysis of patient-derived xenografts of Chinese hepatocellular carcino

来源 :2014医学科学前沿暨第三届个体化治疗与抗肿瘤药物研究新趋向研讨会 | 被引量 : 0次 | 上传用户:cxwycn
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths.Patient derived xenografts (PDX),generated by direct engraftment of tumor samples from the patients into immunocompromised mice can be used as an in vivo platform that provides the opportunity to test personalized medicine strategies.
其他文献
Side population (SP) cells in human nasopharyngeal carcinoma (NPC) are known to be enriched for cancer stem-like cells (CSLCs) and are the main cause of drug-resistance and tumor metastasis.In this st
会议
Dual PI3K/mTOR(phosphatidylinositol 3-kinase/mammalian target of rapamycin) inhibitors are being evaluated clinically for the treatment of tumors with a hyperactivated PI3K/mTOR pathway.However, unexp
会议
The modulation of autophagy is an important component of tumor initiation and progression and ULK1 plays an essential role in macroautophagy and mitophagy.However, the precise regulatory signaling mec
会议
Objective: To explore the role and mechanism of HM910 in cell proliferation on multiple myeloma.Methods: Human multiple myeloma cell lines RPMI-8226, OPM-2, NCI-H929 and U266 were used to perform an M
Objective: Linsitinib, a novel dual insulin-like growth factor 1 (IGF-1R)/insulin receptor (IR) kinase inhibitor in phase Ⅲ clinical trial, was investigated the reversal of multidrug resistance (MDR)
Background: Multidrug resistance (MDR) is a major impediment to the overall success of chemotherapy in clinical oncology.Recently, the intercellular transfer of ABCB1 between tumor cells has been prop
Objective: Largely due to the fact that most of patients suffering from ESCC are diagnosed at advanced states, the 5-year survival rate is merely 19%, which is the fourth worst among all cancers.Thus,
Cancer stem-like cells (CSC) have garnered significant attention as a therapeutic focus, based on evidence they may represent an etiologic root of treatment-resistant cells.Indeed, expression of the m
Lapatinib, a tyrosine kinase inhibitor (TKI), is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2).Lapatinib can modulate the function of A